KROIN DAVID

SEC source: 0001193125-26-342487 · ownership.xml · derivative · entry 2

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 1,957,138 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001193125-26-342487 · ownership.xml · nonDerivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,957,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001193125-26-331058 · ownership.xml · derivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 664,649

Underlying: Common Stock · 286,205 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.exercise_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.expiration_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F3 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001193125-26-046675 · ownership.xml · nonDerivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Persons were tendered in exchange for the Offer Price.

F1 · price: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Persons were tendered in exchange for the Offer Price.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001193125-26-044776 · ownership.xml · derivative · entry 2

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Special Opportunities Fund, LP · CIK 0002077950 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Deep Track Special Opportunities Fund, LP

Disclosed balance after: 93,925

Underlying: Common Stock · 93,925 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.exercise_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.expiration_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F4 · ownership.nature: Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0001193125-26-044776 · ownership.xml · derivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Special Opportunities Fund, LP · CIK 0002077950 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,444

Underlying: Common Stock · 378,444 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.exercise_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire.

F2 · derivative.expiration_date: Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock.

F3 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · derivative · entry 4

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 686,138 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · nonDerivative · entry 3

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Deep Track Special Opportunities Fund, LP

Disclosed balance after: 666,666

F3 · ownership.nature: Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · nonDerivative · entry 2

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,686,138

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0002015536-25-000007 · form4-09162025_100907.xml · nonDerivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 686,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2 · ownership.direct: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0000950170-25-111070 · ownership.xml · nonDerivative · entry 2

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,726,349

F1 · ownership.direct: In addition to Deep Track Biotechnology Master Fund, Ltd., a Cayman Islands exempted company ("DTBMF"), this Form 4 is being filed jointly by Deep Track Capital, LP, a Delaware limited partnership ("Deep Track LP"), and David Kroin, a citizen of the United States of America and the managing member of the general partner of Deep Track LP (together with DTBMF and Deep Track LP, the "Reporting Persons"). Each of the Reporting Persons may be deemed to have a pecuniary interest in the securities reported on this Form 4 (the "Subject Securities"). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.

F2 · ownership.direct: Each of the Reporting Persons may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Securities.

SEC source: 0000950170-25-111070 · ownership.xml · nonDerivative · entry 1

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

Deep Track Capital, LP · CIK 0001856083 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,696,492

F1 · ownership.direct: In addition to Deep Track Biotechnology Master Fund, Ltd., a Cayman Islands exempted company ("DTBMF"), this Form 4 is being filed jointly by Deep Track Capital, LP, a Delaware limited partnership ("Deep Track LP"), and David Kroin, a citizen of the United States of America and the managing member of the general partner of Deep Track LP (together with DTBMF and Deep Track LP, the "Reporting Persons"). Each of the Reporting Persons may be deemed to have a pecuniary interest in the securities reported on this Form 4 (the "Subject Securities"). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.

F2 · ownership.direct: Each of the Reporting Persons may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Securities.

SEC source: 0000950170-24-058720 · ownership.xml · nonDerivative · entry 1

Deep Track Capital, LP · CIK 0001856083 · 10% owner

Deep Track Biotechnology Master Fund, Ltd. · CIK 0002015536 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 18,344,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.745 to $1.81, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.

F2 · ownership.nature: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP. is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, L.P. and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0000930413-17-002350 · c88691_4.xml · nonDerivative · entry 3

GREAT POINT PARTNERS LLC · CIK 0001281446 · 10% owner

JAY JEFFREY R · CIK 0001239607 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Investment Mgr.

Disclosed balance after: 2,216,351

F6 · shares: Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F7 · balance_after: Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F3 · ownership.nature: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0000930413-17-002350 · c88691_4.xml · nonDerivative · entry 2

GREAT POINT PARTNERS LLC · CIK 0001281446 · 10% owner

JAY JEFFREY R · CIK 0001239607 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Investment Mgr.

Disclosed balance after: 2,231,351

F4 · shares: Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F5 · balance_after: Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F3 · ownership.nature: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

SEC source: 0000930413-17-002350 · c88691_4.xml · nonDerivative · entry 1

GREAT POINT PARTNERS LLC · CIK 0001281446 · 10% owner

JAY JEFFREY R · CIK 0001239607 · 10% owner

KROIN DAVID · CIK 0001397513 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Investment Mgr.

Disclosed balance after: 2,251,351

F1 · shares: Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F2 · balance_after: Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F3 · ownership.nature: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.